Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound. by Rao, M. S. et al.
B9 The Macmillan Press Ltd., 1988
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Summary The hepatic effects of ciprofibrate, a potent peroxisome proliferator, were evaluated in male
C57BL/6N mice, a mouse strain with very low incidence of spontaneous liver tumour development. Dietary
feeding of ciprofibrate (0.0125% or 0.025% w/w) for 2 weeks resulted in a marked proliferation of
peroxisomes (9-fold increase) and several-fold increase (8- to 10-fold) in the activity of peroxisomal /3-
oxidation enzymes. Feeding ciprofibrate at 0.025% concentration for 15 months followed by a 0.0125% for 6
months led to the development of hepatic adenomas in 8/14 (57%) and hepatocellular carcinomas (HCC) in
3/14 (21%) mice. In mice given 0.0125% ciprofibrate for 18 months 5 of 8 (62%) and 3 of 8 (37%) developed
adenomas and HCC respectively. Similar to the findings observed in rats, both the adenomas and HCC were
negative for y-glutamyltranspeptidase. These results in C57BL/6N mice of hepatocarcinogenic effect of
ciprofibrate, a non-genotoxic chemical, indicate that peroxisome proliferation can be used as a reliable
parameter to evaluate the carcinogenicity of hypolipidaemic compounds.
Peroxisome proliferation is a unique phenomenon common
to several structurally diverse chemicals including hypolipid-
aemic drugs, phthalate ester plasticizers, industrial solvents
and tetrazole substituted alkoxyacetophenone (Hess et al.,
1965; Reddy & Krishnakantha, 1975; Moody & Reddy,
1978; Reddy & Lalwani, 1983; Elcombe et al., 1985; Eacho
et al., 1986). Of these chemicals, the biological effects of
hypolipidaemic drugs and phthalate esters have been exten-
sively studied (Reddy & Lalwani, 1983; Reddy et al., 1982a;
Cohen & Grasso, 1981; Lake et al., 1984; Reddy & Rao,
1986; Rao & Reddy, 1987). The immediate hepatic effects of
these compounds are hepatomegaly secondary to hyperplasia
and hypertrophy of parenchymal cells and marked proli-
feration of peroxisomes (Moody et al., 1977; Reddy et al.,
1979; Reddy & Lalwani, 1983; Gray & de la Iglesia, 1984).
Peroxisome proliferation is associated with a dispropor-
tionate increase in the activities of several peroxisomal
enzymes. Hydrogen peroxide generating enzymes of the fatty
acid f-oxidation system are increased by several fold, wher-
eas catalase, the enzyme that degrades H202 is induced
minimally and urate oxidase activity remains unaltered
(Lazarow & deDuve, 1976; Hashimoto, 1982; Moody &
Reddy, 1978; Lake et al., 1984; Reddy et al., 1986b; Usuda
et al., 1988). These early hepatic effects remain invariant as
long as the hypolipidaemic compounds are administered and
regress as soon as the treatment is discontinued (Moody &
Reddy, 1976; Miyazawa et al., 1980). Although the
magnitude of peroxisome proliferation is different in
different species, the hypolipidaemic compounds were shown
to induce peroxisomes in rodents, non-rodents and primates
(Gray & de la Iglesia, 1984; Reddy et al., 1984; Lalwani et
al., 1985). The exact mechanism by which the structurally
diverse chemicals induce peroxisome proliferation is not
clear. The present experimental evidence indicates that the
hypolipidaemic compounds most likely act through a cyto-
solic receptor-mediated mechanism (Lalwani et al., 1983;
Reddy & Rao, 1986; Lalwani et al., 1987).
Another intriguing aspect of xenobiotics that are asso-
ciated with an increase in peroxisomes is their hepatocarcino-
genic property in rats and mice, despite their inability to
interact with and damage DNA (Warren et al., 1980; Gupta
et al., 1985). Since the initial observation of the carcinogenic
effect of nafenopin in acatalasemic mice by Reddy and his
associates (1976), several hypolipidaemic compounds have
been shown to induce liver tumours (Reddy & Rao, 1977;
Reddy et al., 1979; Svoboda & Azarnoff, 1979; Reddy et al.,
1980; Lalwani et al., 1981; Rao et al., 1984; Kluwe et al.,
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1985; Rao et al., 1987). The mechanism of induction of liver
tumours by hypolipidaemic compounds remains an intrigue
because they are nonmutagenic in prokaryotic and eukary-
otic test systems in vitro and do not bind and damage DNA
(Warren et al., 1980; Glauert et al., 1984; Butterworth et al.,
1984; Agarwal et al., 1985; Gupta et al., 1985; Goel et al.,
1985). It has been proposed by Reddy and coworkers that
the hepatocarcinogenicity of peroxisome proliferators is due
to the oxidative stress generated by disproportionate increase
of peroxisomal enzymes (Reddy et al., 1982b; Reddy &
Lalwani, 1983; Reddy & Rao, 1986; Rao & Reddy, 1987).
This hypothesis is supported by the observations that
hepatocarcinogenic potency of these compounds is depen-
dent on their ability to induce peroxisome proliferation
(Reddy et al., 1986a; Elcombe et al., 1985; Tomaszewski et
al., 1986).
To further evaluate this hypothesis we have examined the
peroxisome proliferative and hepatocarcinogenic effect of
ciprofibrate in C57BL/6N mice, a highly tumour-resistant
strain. In C57BL/6N mice the incidence of spontaneous
tumours is very rare (less than 5% at 2 years of age) (Grasso
and Hardy, 1975). Because of the rare occurrence of sponta-
neous lesions, the development of hepatocellular tumours in
this experiment would clearly indicate that ciprofibrate is a
complete carcinogen, rather than a tumour promotor.
Materials and methods
Animals
Male C57BL/6N inbred mice, weighing 18 to 20g (5 to 6
weeks old), were purchased from Charles River Laboratories
Inc. (Wilmington, MA). They were housed in groups of 5 in
plastic cages on San-i-cel bedding in an air-conditioned room
with a 12-hour light and dark cycle. All the animals had free
access .to water.
Short-term studies
In this experiment, the effect of ciprofibrate (2-[4-(2,2-
dichlorocyclopropyl)phenoxy]-2methylpropionic acid) on per-
oxisome proliferation and induction of peroxisome-asso-
ciated enzymes was investigated. Fifteen mice were divided
into 3 equal groups of 5 each. The first 2 groups were given
ciprofibrate (purity >99.9% by TLC, Sterling-Winthrop
Research Institute, Rensselaer, NY) in ground chow for 2
weeks at concentrations of 0.0125 and 0.025% (w/w in
chow) respectively. Group 3, which served as control, was
given ground chow without ciprofibrate. The animals were
not starved before sacrifice. All the animals were killed
under ether anaesthesia between 9:00 and 10:00am.
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Table I Effects of ciprofibrate treatment on weight and peroxisomal enzymes of liver in
C57BL/6N mice
Relative [I- Cl4]palmitoyl- Accyl-CoA
liver weight Catalase coA-oxidation oxidase
Treatment (g 100g- (units mg-1 (pmolmin -1 g- (units g- 1
(2 wk) body wt) proteina) livera) livera)
Control 5.74+0.23 41.2+ 1.78 1.79+0.14 2.07+0.06
0.0125% (w/w)b 10.19+0.19c 74.16+2.18c 17.44+0.80c 15.95+0.44C
0.025% (w/w)b 12.32+0.32c 78.28+2.15C 15.51 +0.78c 14.65+0.65C
aMean+s.e.m. of 5 animals; bCiprofibrate was mixed in powdered chow It the levels
indicated (w/w); cSignificantly different from controls (P<0.001, Students' t test).
Table II Morphometric analysis of ciprofibrate-induced per-
oxisome proliferation in the parenchymal cells of liver in
C57BL/6N mice
% of cytoplasmic volumea
Peroxisomes Mitochondria
Control 1.75 15.30
Ciprofibrateb 16.12C 12.60
aMorphometric analysis was done on pictures from each
animal according to the procedure of Weibel (1969);
bCiprofibrate was given in diet for 2 weeks at a concentration
of 0.0125%; cSignificantly increased over the control
(P<0.001, Students' t test).
Table III Incidence and pattern of liver lesions in C57BL/6N mice treated with
ciprofibrate
No. of animals
Total no. Effective with tumours Adenomas HCC
of mice no. (0) (%) (%)
Ciprofibratea 20 14 8 (57)C 8 (57) 3 (21)
0.025%
Ciprofibrateb 8 8 6 (75)C 5 (62) 3 (37)
0.0125%
Control 12 12 0 0 0
5 adenomas and 3 carcinomas were negative for CGT. aCiprofibrate was given in
diet at a concentration of 0.025% for 15 months and 0.0125% for the remainder of
the experiment; bCiprofibrate was given in diet at a concentration of 0.0125%
throughout the experiment; CP<0.005 (Chi2-test).
Enzyme assay
The activities of peroxisome-associated enzymes, catalase,
fatty acyl-CoA oxidase and peroxisomal palmitoyl-CoA oxi-
dation were measured according to the procedures described
before (Luck, 1965; Small et al., 1985; Lazarow, 1981). Total
protein concentrations were determined by the procedure of
Lowry et al. (1951).
Morphometric analysis ofperoxisomes
Portions of liver from all animals given ciprofibrate at
0.0125% and controls were fixed in 2.5% glutaraldehyde in
0.1 M sodium cacodylate buffer for 1 h, and post-fixed in 1%
osmium tetroxide in 0.1M S-collidine buffer, pH 7.4 for I h
and processed for electron microscopy (Reddy et al., 1984).
Ultrathin sections were stained with uranyl acetate and lead
citrate and examined in a JEOL JEM-100 CX 11 electron
microscope. Volume density of peroxisomes was determined
by the point counting method of Weibel (1969). From each
animal 10 electron micrographs were analyzed.
Carcinogenesis experiment
Twenty male C57BL/6N mice (5 to 6 weeks of age) were fed
ciprofibrate in ground chow at a concentration of 0.025%
(w/w) for 15 months, and 0.0125% for 6 more months, at
which time the experiment was terminated. Another group of
8 mice were maintained on 0.0125% ciprofibrate from the
beginning and killed at the end of 18 months. Twelve control
mice were fcl the same ground chow ad libitum without
ciprofibrate. A complete autopsy was performed in all the
animals that died or were sacrificed. Livers were excised and
examined for gross lesions after serial sectioning. Represen-
tative sections were fixed in 100% neutral buffered formalin
and processed for routine histological examination. Some
sections from the tumours were fixed in ethanol-acetic acid
and processed for histochemical localization of y-glutamyl-
transpeptidase (Rao et al., 1987; Rutenburg et al., 1969).
Portions of tumours and adjacent liver were processed for
transmission electron microscopy. In addition, sections from
lungs, pancreas and kidneys were also processed for light
microscopy.
Results
Early changes
Acute hepatic effects of ciprofibrate on weight and peroxi-
some-associated enzymes are summarized in Table I. The
liver weight increased by 1.8- and 2.1-fold in mice fed 0.0125
and 0.025% ciprofibrate respectively, over the controls.
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Catalase activity was increased by 1.9-fold, and the activities
of fatty acyl-CoA oxidase and the peroxisomal palmitoyl-
CoA oxidation increased by -8- and 10-fold respectively.
The volume density of peroxisomes increased by 9-fold over
the control values (Figure 1, Table II).
Carcinogenesis studies
Of the 20 mice that were maintained on 0.025% ciprofibrate,
6 died between 12 and 14 months. Because of the increased
mortality the concentration of ciprofibrate was reduced to
0.0125% from the beginning of the 15th month. Between 15
and 21 months 8 animals died, and of the remaining 6 mice
2 were killed at 16 months and 4 at 21 months. None of the
animals that died before 15 months developed liver tumours.
Livers in these animals were markedly enlarged and histo-
logically showed focal areas of necrosis and minimal fatty
change.
Of the 14 mice that died or were killed between 15 and 21
months, 8 developed adenomas and 3 had HCC. The
animals that were maintained on 0.0125% ciprofibrate all
survived until the termination of the experiment at 18
months. In this group 5 of 8 and 3 of 8 mice developed
adenomas and HCC respectively. The incidence and the type
of liver tumours in both the groups are shown in Table III.
Grossly, the livers of these animals were markedly enlarged,
and showed one to multiple greyish nodules ranging from 2
to 9mm in diameter. Histologically, the liver tumours were
either hepatic adenomas (Figure 2) or well-differentiated
trabecular type hepatocellular carcinomas (Figure 3). In all
these animals with liver tumours, several of eosinophilic or
clear cell type altered foci were present. Other histological
findings in the livers included focal areas of ischaemic
necrosis, peliosis, spongiosis (areas of cystic degeneration),
amyloidosis and focal bile-duct proliferation. In 3 animals
marked endothelial cell proliferation was observed around
the areas of necrosis. Pulmonary metastases were not seen in
mice with hepatocellular carcinomas. All liver tumours
(nodules and carcinomas) that were examined for y-glutamyl
transpeptidase (CGT) were negative for this enzyme (Figure
4). Similarly 4 of the 5 altered areas were also negative for
CGT, but one which contained few dysplastic cells was
weakly positive. Ultrastructurally, cells of HCC showed
good differentiation containing round nuclei, well developed
cytoplasmic organelle and frequent bile canaliculi. Increased
number of peroxisomes were seen in many cells, although the
number varied fromm cell to cell (Figure 5). The hepatocytes
from uninvolved liver (nontumourous portion) also showed a
marked increase in peroxisomes. Lipofuscin was slightly
increased. No hepatic lesions were observed in any of the 12
control mice. No significant histological changes were
observed in lungs and pancreas. Kidneys of some of the
animals showed amyloidosis.
Discussion
For evaluating the carcinogenic potential of several chemi-
cals which include both the genotoxic and nongenotoxic
agents, rats and mice are being extensively used for carcino-
genesis bioassay. However, the value of mice as an experi-
mental model for these tests is questioned because of the
very high incidence of spontaneous tumours. The rate of
spontaneous hepatic tumour development is highly variable
and dependent on the genetic makeup of the animal. In male
C3H mice the spontaneous tumour incidence is about 30-
50%, and 20-30% in B6C3F1 mice (Ruebner et al., 1984;
Ward, 1980). In contrast, the incidence of these tumours in
C57BL/6N mice is very low or virtually non-existent (Grasso
& Hardy, 1975).
In the present study, we have used C57BL/6N mice to
examine the acute and chronic effects of ciprofibrate on
hepatic peroxisome proliferation and liver tumour induction
to ascertain whether there is any correlation between peroxi-
Figure 1 Electron micrograph of hepatocyte from a mouse
treated with 0.0125% ciprofibrate for 2 weeks showing marked
increase in the number of peroxisomes (p). ( x 3,892)
Figure 2 Photomicrograph of hepatic adenoma. (H&E x 120)
Figure 3 Well differentiated hepatocellular carcinoma with tra-
becular pattern. (H&E x 120)
Figure 4 y-glutamyltranspeptidase negative hepatocellular carci-
noma (stained for GGT by the procedure of Rutenburg et al.,
and counterstained with hematoxylin). (x 180)
some proliferation and tumour development in this resistant
strain which develops no spontaneous liver tumours. Admi-
nistration of ciprofibrate for 2 weeks resulted in peroxisome
proliferation and induction of peroxisome-associated
enzymes to nearly the same extent at both the dose levels.
This indicates that with 0.0125% a maximum effect is
produced. The magnitude of response observed in mice isHEPATOCARCINOGENESIS BY CIPROFIBRATE 49
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Figure 5 Electron micrograph of hepatocellular carcinoma.
Tumour cells show increased numbers of peroxisomes (p).
(x3,750)
comparable to that seen in rats. The increase in catalase
(- 2-fold) and peroxisome volume density ( 10-fold) are
very similar in both the species (Reddy et al., 1986b; Lalwani
et al., 1983). However, peroxisomal palmitoyl-CoA oxidation
increased slightly more in rats (13-fold) than in mice
(9.7-fold).
The carcinogenesis experiments clearly demonstrate that
ciprofibrate is tumourigenic in livers of this highly resistant
strain of mice. The total incidence of liver tumours in high
and low dose groups was 57 and 75% respectively. Interest-
ingly, the incidence of HCC in mice maintained on low dose
of ciprofibrate was almost 2 times more than in high dose
group. The lower incidence of tumours in general and HCC
in particular in the mice maintained on 0.025% ciprofibrate
for 15 months was probably due to the toxic effect of the
drug. In the lower dose group also the incidence of HCC
(37%) was low in comparison to the tumour incidence
(100%) observed in rats (Rao et al., 1984). This difference
was probably because of the short duration of the expen-
ment; if the experiment was continued up to the end of 2
years it is conceivable that we may have observed a higher
incidence of HCC.
A correlation between the potency of hypolipidaemic
compounds in inducing peroxisome proliferation and induc-
tion of liver tumours in rats has been clearly established
(Reddy et al., 1986a; Reddy & Lalwani, 1983). Similarly, a
direct correlation for peroxisome proliferation and carcino-
genic effects of trichloroethylene has also been shown. Tri-
chloroethylene, which is carcinogenic in mice but not in rats
was shown to be a peroxisome proliferator in mice; but not
in rats (National Toxicology Program, 1983; Elcombe et al.,
1985). The results of these different experiments further
support the hypothesis that hepatocarcinogenicity of hypo-
lipidaemic compounds is dependent on their biological
activity of peroxisome proliferation (Reddy et al., 1980;
Reddy & Lalwani, 1983).
Neoplastic transformation is associated with acquisition ol
several foetal properties. Making use of the phenotypic
changes in hepatocarcinogenesis of rats and mice enzyme
markers are frequently used to identify preneoplastic and
neoplastic hepatocytes (Tatematsu et al., 1982; Essigmann &
Newberne, 1981; Lipsky et al., 1981). GGT, a membrane-
bound enzyme, is frequently used as a phenotypic marker for
rat hepatic neoplasia induced by genotoxic carcinogens
(Tatematsu et al., 1982; Pugh & Goldfarb, 1978). Interest-
ingly, the preneoplastic and neoplastic lesions of liver
induced by several types of hypolipidaemic compounds in
rats are negative for GGT, which has been attributed to the
failure of derepression CGT gene activity (Rao et al., 1986a;
Rao et al., 1986b; Rao & Reddy, 1987; Rao et al., 1987).
The results of the histochemical study of this experiment
were like those observed in rats, i.e., both the adenomas and
HCC did not express GGT. However, in mice GGT expres-
sion is not considered as a true marker for assessing
neoplastic transformation since its expression was unpredic-
table and depended on the carcinogens used. In tumours
induced by safrole, all types of hepatic lesions were positive
for GGT (Lipsky et al., 1981), whereas the spontaneously
developed or other chemically induced tumours were nega-
tive (Fiala et al., 1972; Essigmann & Newberne, 1981;
Ohmori et al., 1981).
Based on the mechanism of action, chemical carcinogens
are divided into genotoxic and non-genotoxic chemicals
(Weisburger & Williams, 1981; Reddy et al., 1983). The
genotoxic chemicals covalently react with DNA, leading to
somatic mutation resulting in the development of initiated
cells. To screen the genotoxic carcinogens there are several
short-term in vivo and in vitro assays that measure DNA
damage, mutagenic effects and chromosomal aberrations
(McCann et al., 1975; Williams, 1979; Yamasaki et al.,
1982). However, there are no short-term tests to screen non-
genotoxic carcinogens. It has been suggested by Reddy et al.
(1983) that evaluation of the biological activity of these
chemicals can be used to predict their carcinogenicity.
Several chemicals belonging to the group of non-genotoxic
carcinogens, that are known hepatocarcinogens, are shown
to induce smooth endoplasmic reticulum and microsomal
Phase 1 drug metabolizing enzymes, proliferation of mito-
chondria or peroxisomes (Staubli et al., 1969; Kimbrough,
1979; Reznik-Schiiller & Lijinsky, 1981; Reddy & Lalwani,
1983). With hypolipidaemic compounds there is a good
correlation between the potency of peroxisome proliferation
and hepatocarcinogenicity. Because of this well established
association, it is reasonable to assume that evaluation of
induction of peroxisome proliferation will serve as a useful
and practical test to screen non-genotoxic chemicals and also
to predict their carcinogenic effect in different species of
animals. The results of the experiment further support this
notion because of the development of hepatocellular tumours
in this highly tumour-resistant strain of mice correlates well
with the peroxisome proliferation observed in short-term
experiment.
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